Quick Answer
ELITE PHARMACEUTICALS INC /NV/ reported Revenue From Contract With Customer Excluding Assessed Tax of $84.04 million for the year ending 2025.
- ELITE PHARMACEUTICALS INC /NV/ showed an increase of +48.4% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
- This data is from ELITE PHARMACEUTICALS INC /NV/'s annual report (Form 10-K), filed with the SEC on June 30, 2025.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 5 years of available data (2021 to 2025), ELITE PHARMACEUTICALS INC /NV/'s Revenue From Contract With Customer Excluding Assessed Tax has grown by 231.1%.
- Historical annual values: Fiscal year 2025: $84.04 million | Fiscal year 2024: $56.63 million | Fiscal year 2023: $34.16 million | Fiscal year 2022: $32.26 million | Fiscal year 2021: $25.38 million.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: